ALK and chronic myelogenous leukemia, BCR-ABL1 positive: However, the success of targeted molecular therapy, such as imatinib toward the BCR::ABL gene fusion in CML (Druker 2008; Druker et al. 2001a,b), larotrectinib toward NTRK-fusion-positive cancers (Drilon et al. 2018), and ALK inhibitors toward ALK-fusion-positive cancers (Lin et al. 2017), provides hope that targeting additional gene fusions may inhibit a variety of cancers for which there are few therapeutic options.